HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

Beijing Luzhu Biotechnology / Equity Capital Markets

<ul>
<li>Either vaccines or therapeutic biologics, Luzhu’s clinical progress has no advantages. There have been quite a few competing products on the market or candidates with faster development progress than Luzhu.</li>
<li>Luzhu applies the low price strategy to open the market. We're not sure if it works or not, since it still depends on R&amp;D efficiency, product quality and commercialization capabilities.</li>
<li>We tend to be conservative about the Company's prospects because its eventual revenue scale and profit margins are likely to be very limited based on our analysis.</li>
</ul>


Either vaccines or therapeutic biologics, Luzhu’s clinical progress has no advantages. There have been quite a few competing products on the market or candidates with faster development progress than Luzhu.
Luzhu applies the low price strategy to open the market. We're not sure if it works or not, since it still depends on R&amp;D efficiency, product quality and commercialization capabilities.
We tend to be conservative about the Company's prospects because its eventual revenue scale and profit margins are likely to be very limited based on our analysis.


Pre-IPO Beijing Luzhu Biotechnology - The Eventual Revenue Scale and Profit Margins Could Be Limited

China

Beijing Luzhu Biotechnology Co., Ltd. operates pharmaceutical development businesses. The Company develops human monoclonal antibodies, bispecific antibody drugs, recombinant viral vaccines, and other products. Beijing Luzhu Biotechnology conducts businesses in China.

Beijing Luzhu Biotechnology (1868402D CH)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Pre-IPO Beijing Luzhu Biotechnology - The Eventual Revenue Scale and Profit Margins Could Be Limited

Clinical progress of Luzhu’s candidates has no advantages.In front of fierce competition, low price strategy may not work,leading to limited...

Xinyao (Criss) Wang